Halfway through February, seven different sources of funding for health care and life science innovations have announced newly raised pools of cash totaling $2.2bn for a wide array of technologies, including biopharmaceutical products.
On 18 February alone, five different funders revealed $1.7bn available for new investments. This is in addition to Abingworth’s $465m...






